BETHESDA, MD and NEW YORK, NY—In a groundbreaking alliance poised to transform gastrointestinal healthcare access, Forus, an AI-driven platform specializing in medication access automation, has partnered with the American Gastroenterological Association (AGA), a leading medical society devoted to advancing digestive health science and practice. This collaboration aims to streamline the treatment initiation process for over 60 million Americans affected by digestive diseases.
Forus leverages artificial intelligence to revolutionize the traditional medication access pathway by automating prior authorizations, appeals, financial assistance, and pharmacy routing. Embedded seamlessly within electronic health record (EHR) systems, Forus addresses systemic inefficiencies that cause treatment delays, enabling faster transitions from prescription to patient delivery. This AI integration is universally compatible with all drugs, insurance payors, and pharmacies nationwide, ensuring broad applicability without additional cost burdens on providers or patients.
The AGA brings its extensive clinical expertise and patient advocacy capabilities to the partnership, grounded in rigorous, evidence-based guidelines for digestive disease management. Gastrointestinal patients frequently encounter obstructive hurdles when accessing prescribed therapies—even with clear clinical indications—a challenge this collaboration directly targets by combining clinical insight with AI-powered data analytics.
“Digestive care is evolving rapidly, yet patients’ access to novel therapies often lags behind,” said Sahir Jaggi, CEO and founder of Forus. “Our technology captures real-time data on the medication journey, spotlighting access barriers that may otherwise remain invisible. Teaming with AGA allows us to channel these insights into effective advocacy and improved clinical outcomes.”
AGA’s vice president of clinical and scientific affairs, Alison Kim, PhD, emphasized the partnership’s potential to enhance advocacy efforts: “Integrating Forus’s AI-generated intelligence strengthens our ability to identify and address systemic obstacles, reinforcing our commitment to both clinicians and patients. This collaboration expands the toolkit we have to influence payors, policymakers, and healthcare delivery.”
The integration of Forus’s platform within clinical workflows promises not only to minimize administrative delays but also to reduce the incidence of cost-related treatment abandonment, a significant issue in managing chronic gastrointestinal disorders. By preemptively addressing financial barriers and automating insurance processes, the platform ensures that prescribed medications reach patients more reliably and swiftly.
Looking ahead, the partnership is designed to evolve continuously, with ongoing analysis and dissemination of findings aimed at benefiting the broader gastroenterology community. This model exemplifies how the convergence of medical society leadership and cutting-edge AI technology can pioneer new standards in equitable healthcare access.
Such innovation may set a precedent for other specialty fields, illustrating the transformative power of AI to bridge the gap between clinical research and patient experience, ultimately accelerating therapeutic delivery and improving health outcomes on a national scale.
Subject of Research: AI-powered automation in medication access for gastrointestinal diseases
Article Title: AI and Gastroenterology Alliance Aims to Revolutionize Medication Access for Millions
News Publication Date: July 8, 2026
Web References: https://forus.com/, https://www.gastro.org/
Keywords
Gastroenterology, AI in healthcare, medication access, prior authorization automation, digestive diseases, clinical advocacy, electronic health records, healthcare innovation
